|Title||Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.|
|Authors||Marko Skrtić, Shrivani Sriskanthadevan, Bozhena Jhas, Marinella Gebbia, Xiaoming Wang, Zezhou Wang, Rose Hurren, Yulia Jitkova, Marcela Gronda, Neil Maclean, Courteney K Lai, Yanina Eberhard, Justyna Bartoszko, Paul Spagnuolo, Angela C Rutledge, Alessandro Datti, Troy Ketela, Jason Moffat, Brian H Robinson, Jessie H Cameron, Jeffery Wrana, Connie J Eaves, Mark D Minden, Jean C Y Wang, John E Dick, Keith Humphries, Corey Nislow, Guri Giaever, Aaron D Schimmer|
|Abstract||To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identified mitochondrial translation inhibition as the mechanism of tigecycline-mediated lethality. Tigecycline selectively killed leukemia stem and progenitor cells compared to their normal counterparts and also showed antileukemic activity in mouse models of human leukemia. ShRNA-mediated knockdown of EF-Tu mitochondrial translation factor in leukemic cells reproduced the antileukemia activity of tigecycline. These effects were derivative of mitochondrial biogenesis that, together with an increased basal oxygen consumption, proved to be enhanced in AML versus normal hematopoietic cells and were also important for their difference in tigecycline sensitivity.|
|Citation||Cancer Cell 2011; 20:674-88|
YeastPhenome.org is running in beta version. The data are available for download, but, as of today, we cannot guarantee lack of errors or code bugs introduced during processing. This warning will be removed after all cross-checks and validations have been completed. In the meantime, please, be careful when using the data.